HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Impact of incretin-related agents on endothelial cell function

Creative Commons License

Files in This Item:
ClinTranslDegenerDis217-1078419_025944.pdf300.12 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/67909

Title: Impact of incretin-related agents on endothelial cell function
Authors: Nomoto, Hiroshi Browse this author
Miyoshi, Hideaki Browse this author →KAKEN DB
Nakamura, Akinobu Browse this author →KAKEN DB
Atsumi, Tatsuya Browse this author →KAKEN DB
Manda, Naoki Browse this author
Kurihara, Yoshio Browse this author
Aoki, Shin Browse this author
on behalf of SAIS Study Group Browse this author
Keywords: GLP-1 analogue
DPP-4 inhibitor
endothelial cell function
Issue Date: Jan-2017
Publisher: Wolters Kluwer
Journal Title: Clinical Trials in Degenerative Diseases
Volume: 2
Issue: 1
Start Page: 7
End Page: 11
Publisher DOI: 10.4103/2542-3975.202726
Abstract: Incretin-related drugs, such as dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, have been clinically available and widely used to treat patients with type 2 diabetes mellitus. Accumulating evidence indicates that these agents exert glycemic control and have various other favorable effects, including prevention of atherosclerosis. It is important to assess and manage early-phase atherosclerosis, but whether diabetic therapeutics including incretin-related drugs improve or maintain vascular endothelial cell function has not been fully determined. We previously published prospective clinical trials focused on flow-mediated dilation in patients with type 2 diabetes, who did not have severe atherosclerosis, using two different incretin-related drugs: a DPP-4 inhibitor and a GLP-1 analogue. These trials showed that these therapeutic agents did not improve endothelial cell function. In this article, we discuss how incretin-related drugs contribute, if at all, to vascular endothelial cell function, atherosclerosis, and beta-cell function, based on our clinical trials and previous evidence.
Rights: http://creativecommons.org/licenses/by-nc-sa/3.0/
Type: article
URI: http://hdl.handle.net/2115/67909
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 三好 秀明

Export metadata:

OAI-PMH ( junii2 , jpcoar )


 

Feedback - Hokkaido University